Calcium Sulfate Hemihydrate Nanowires: One Robust Material in Separation of Water from Water-in-Oil Emulsion.

Here we report a facile and cost-effective wet-chemical approach to the synthesis of calcium sulfate hemihydrate nanowires (HH NWs, CaSO4·0.5H2O), and their robust performance in immobilizing water molecules to the crystal lattice of CaSO4 and then separating them from a surfactant-stabilized water-in-oil emulsion (mean droplet size of around 1.2 µm). Every gram of HH NWs are capable of treating 20 mL emulsion (water content: 10.00 mg mL-1) with a separation efficiency of 99.23% at room temperature, and this efficiency can be further improved by tuning the surface charge density of HH. Along with the water immobilization, HH NWs are converted to large cubic-like calcium sulfate dihydrate microparticles (DH, CaSO4·2H2O, mean size: 50 µm), and the accompanied size increment enables efficient collection of the solid phase from oil. DH microparticles can be regenerated into HH NWs, which retain the high performance of the original NWs. Such a unique renewable feature improves the economics of our method and simultaneously prevents the secondary pollution. Further economic evaluation finds that purification of every cubic meters of emulsion (water content: 10.00 mg mL-1) will cost about $34.18 for HH NWs, much lower than the $490.78 for the previously reported HH NPs, and $11 052.05-$23 420.32 Fe3O4 NP-based adsorbents, respectively. With the high efficiency, easy collection, low cost, and renewable feature, HH NWs show highly promising applications in the field of oil purification and recycle.

Household expenditures on dietary supplements sold for weight loss, muscle building, and sexual function: Disproportionate burden by gender and income.

Dietary supplements sold for weight loss (WL), muscle building (MB), and sexual function (SF) are not medically recommended. They have been shown to be ineffective in many cases and pose serious health risks to consumers due to adulteration with banned substances, prescription pharmaceuticals, and other dangerous chemicals. Yet no prior research has investigated how these products may disproportionately burden individuals and families by gender and socioeconomic position across households. We investigated household (HH) cost burden of dietary supplements sold for WL, MB, and SF in a cross-sectional study using data from 60,538 U.S. households (HH) in 2012 Nielsen/IRi National Consumer Panel, calculating annual HH expenditures on WL, MB, and SF supplements and expenditures as proportions of total annual HH income. We examined sociodemographic patterns in HH expenditures using Wald tests of mean differences across subgroups. Among HH with any expenditures on WL, MB, or SF supplements, annual HH first and ninth expenditure deciles were, respectively: WL $5.99, $145.36; MB $6.99, $141.93; and SF $4.98, $88.52. Conditional on any purchases of the products, female-male-headed HH spent more on WL supplements and male-headed HH spend more on MB and SF supplements compared to other HH types (p-values < 0.01). High-income ($30,000 < annual income < $100,000), compared to low-income (annual income < $30,000) HH, spent more on all three supplements types (p-values < 0.01); however, proportional to income, low-income HH spent 2-4 times more than high-income HH on WL and MB supplements (p-values < 0.01). Dietary supplements sold for WL, MB, and SF disproportionately burden HH by income and gender.

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.

CONTEXT: Epoetin therapy for dialysis-related anemia is the single largest Medicare drug expenditure. The type of facility (profit, chain, and affiliation status) at which a patient receives dialysis might affect epoetin dosing patterns and has implications for future epoetin policies. OBJECTIVE: To examine the association between dialysis facility ownership and the dose of epoetin administered. DESIGN, SETTING, AND PARTICIPANTS: Data from the US Renal Data System were used to identify 159,522 adult Medicare-eligible, end-stage renal disease patients receiving in-center hemodialysis during November and December 2004. Regression models were used to estimate the mean epoetin dose and dose adjustment by profit, chain, and affiliation status. MAIN OUTCOME MEASURES: Weekly mean epoetin dose administered in December 2004 and the adjustment in dose between November and December 2004. RESULTS: Compared with patients in nonprofit dialysis facilities (n = 28,199), patients in large for-profit dialysis chain facilities (n = 106,116) were consistently administered the highest doses of epoetin regardless of anemia status. Compared with nonprofit facilities, for-profit facilities administered, on average, an additional 3306 U/wk of epoetin. Among the 6 large chain facilities with a similar patient case-mix, the average dose of epoetin ranged from 17,832 U/wk at chain 5 (nonprofit facilities with a mean hematocrit level of 34.6%) to 24,986 U/wk at chain 2 (for-profit facilities with a mean hematocrit level of 36.5%). Dosing adjustments also differed by type of facility. On average, compared with nonprofit facilities, for-profit facilities increased epoetin doses 3-fold for patients with hematocrit levels of less 33% and also increased the doses among patients with hematocrit levels in the recommended target of 33% to 36%, especially in the largest for-profit chain facilities. The greatest difference in dosing practice patterns between facilities was found among patients with hematocrit levels of less than 33%. CONCLUSIONS: Dialysis facility organizational status and ownership are associated with variation in epoetin dosing in the United States. Different epoetin dosing patterns suggest that large for-profit chain facilities used larger dose adjustments and targeted higher hematocrit levels.